StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30243% above fair value
$144.67−3.69 (-2.49%)

Close on Nov 3, 2026Market cap $356.93BP/E 115.7Yield 2.27%

Merck NuvaRing by Year

NuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%) (%)

Merck NuvaRing: -73.0% in FY2020, down 70.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
-73.0%
Period ended Dec 31, 2020
Change on a year earlier
-70.0 pts
-3.0% in FY2019
History
4 years
Since FY2017
Sources
4
Documents cited below

Where the FY2020 figure comes from

“|| NuvaRing | 63 | 63 | 58 | 53 | 236 | 219 | 240 | 241 | 179 | 879 | -70 | -70 | -73 | -73”

Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2020Dec 31, 2020-73.0%-70.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2019Dec 31, 2019-3.0%-22.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 201819.0%+21.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017-2.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck NuvaRing (%), annual FY2017–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-nuvaring-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?